GU Cancer Genomics Expert
Dr. Wyatt is an associate professor in Urologic Sciences at the University of British Columbia, Canada. He is a senior research scientist at the Vancouver Prostate Centre and a senior scientist at BC Cancer. Dr. Wyatt has a DPhil in genetics from the University of Oxford. His research goals are to identify associations between genomic alterations and patient outcomes in metastatic prostate and bladder cancer, and to translate these findings into clinical biomarkers. Dr. Wyatt has developed novel laboratory and computational techniques to study plasma circulating tumour DNA (ctDNA). Through application of these methods to clinical trial cohorts, his team has demonstrated that ctDNA is highly representative of metastatic lesions, and that somatic alterations detected in ctDNA can help predict prostate cancer therapy resistance or response.
Moderated by the Oncology Brothers. Episode 1 of a 3-part video podcast series
GU CONNECT has developed a comprehensive resource which is available on ESMO OncologyPRO, providing information on PARP inhibitors in prostate cancer